Edgar Filing: Capstone Therapeutics Corp. - Form S-8 POS

Capstone Therapeutics Corp. Form S-8 POS March 21, 2019			
As filed with the United States Securities and Exchange Commission on March 21, 2019			
Registration No. 333-134980			
UNITED STATES			
SECURITIES AND EXCHANGE COMMISSION			
Washington, D.C. 20549			
Post-Effective Amendment No. 1 to			
Form S-8 Registration Statement			
UNDER THE SECURITIES ACT OF 1933			
CAPSTONE THERAPEUTICS CORP.			
(Exact name of registrant as specified in its charter)			

Delaware86-0585310(State or other jurisdiction of(I.R.S. Employer

incorporation or organization) Identification No.)

1275 W. Washington Street, Suite 104
Tempe, Arizona 85281
(Address of Principal Executive Offices) (Zip Code)

Capstone Therapeutics Corp. 2005 Equity Incentive Plan (f/k/a OrthoLogic Corp. 2005 Equity Incentive Plan)			
(Full title of the plan)			
Les M. Taeger	Copy to: Jacque Westling		
Senior Vice President, Chief Financial Officer, Capstone Therapeutics Corp. 1275 W. Washington Street, Suite 104		Quarles & Brady LLP Renaissance One, Two North Central Avenue	
Tempe, AZ 85281	ct, Suite 104	Phoenix, AZ 85004	
(Name and address of agent for service)			
(602)-286-5520 (Telephone number, including area code, of agent for service)			
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.			
Large accelerated filer	Accelerated filer		
Non-accelerated filer Smaller reporting company Emerging growth company			

Edgar Filing: Capstone Therapeutics Corp. - Form S-8 POS

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

DEREGISTRATION OF SECURITIES

Capstone Therapeutics Corp. (the "Registrant") is filing this Post-Effective Amendment No. 1 (this "Post-Effective Amendment") to the Registration Statement on Form S-8, No. 333-134980 (the "Registration Statement") to terminate the effectiveness of the Registration Statement and to remove from registration all securities that remain unsold under the Capstone Therapeutics Corp. 2005 Equity Incentive Plan (f/k/a OrthoLogic Corp. 2005 Equity Incentive Plan).

Edgar Filing: Capstone Therapeutics Corp. - Form S-8 POS

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Tempe, State of Arizona, on March 21, 2019.

CAPSTONE THERAPEUTICS CORP.

By:/s/Les M. Taeger Les M. Taeger Senior Vice President and Chief Financial Officer

No other person is required to sign these Post-Effective Amendments on behalf of the Registrant in reliance upon Section 478 of the Securities Act of 1933, as amended.